

IN THE CLAIMS

Please add Claims 46-50 shown below:

46. The pharmaceutical composition according to claim 10, wherein the HLA Class I molecule is HLA-A2.

47. The kit according to claim 18, wherein the encoded CEA comprises an epitope YLSGANLN (Seq. ID No:1).

48. The kit according to claim 19, wherein the immunostimulatory molecule is GM-CSF.

49. The method according to claim 30, wherein the tumor is a colorectal tumor.

50. The method according to claim 30, wherein the CEA epitope is YLSGANLN (Seq. ID No:1).

REMARKS

Claims 1-50 are pending in the application. Claims 46-50 have been newly added as a result of this Amendment.

Support for the subject matter of Claim 46 is found, *inter alia*, in Figure 3, Figures 5A-5B, Figures 7A-7B, and on page 15, lines 15-17 in the application as originally filed. Support for the subject matter of Claim 47 is found, *inter alia*, on page 13, lines ° to 6 in the application as originally filed. Support for the subject matter of Claim 48 is found *inter alia*, on page 2, lines 23-33 to page 3, line °, and on page 11, lines 13-14 in the application as originally filed. Support for the subject matter of Claim 49 is found *inter alia*, on page 1, lines 9-11 in the application as